Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.